Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry.
Report: Swiss drugmaker Roche among several large firms targeted by hackers
According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.
Mayo Clinic Platform Program to Help Clinical Digital Health Startups Succeed
Mayo Clinic has developed a new tool that could speed up the time it takes for digital health companies to validate their tech to hospitals.
CRO Charles River Labs hacked, data from clients stolen
A spokesperson said the data stolen would not have included patient information. A cybersecurity expert said organizations that aggregate data, like CROs, are often a target for criminals as well as foreign espionage groups, especially from China.
Atomwise, Charles River Labs partner to provide AI services in drug discovery
The partnership with the Massachusetts-based CRO could yield up to $2.4 billion in royalties for Atomwise, if projects are successful.
Survey highlights drugmakers’ CRO needs as demand for services grows
The report, by CRO Worldwide Clinical Trials, shows growing need for early-stage development expertise, with high demand for data quality, efficiency and overall trial management.
Obama hails bill averting doc pay cut… for now (Morning Read)
The U.S. House gave final approval on Thursday to a bill that would avert a 25 percent cut in Medicare payments to doctors by freezing reimbursement rates at current levels until the end of next year, reports the New York Times. President Obama, who hailed the nearly unanimous action by Congress, promised to sign the legislation.
Tackling Messy Provider Data with an NPI-Forward Approach
Mike Wirth of ProviderTrust shares insights about the company in this interview at the ViVE 2025 conference in Nashville last month.
Republican wins unlikely to kill health reform law (Morning Read)
Though presumptive House Speaker John Boehner (R-Ohio) says of health reform, "there's a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens," it is likely the law will remain intact in a divided Congress, according to the Washington Post.
Charles River Laboratories, Transposagen Biopharmaceuticals sign deal for lab rats
Transposagen Biopharmaceuticals Inc. signed an exclusive licensing deal with Charles River Laboratories International Inc. (NYSE:CRL) for lab rats. Under the agreement, Wilmington, Mass.-based Charles River will market and distribute the Lexington, Ky.-based lab rat developer’s p53 and Bcrp TGEM Knockout rat models, so named for mutations in their p53 and Bcrp genes. The rats mimic […]
Charles River Labs speeds stock buyback after failed merger
Charles River Laboratories International Inc. (NYSE: CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE: WX), plans to accelerate a $300 million stock buyback and took out a $750 million credit line.
Charles River, Wuxi PharmTech still on a roller coaster
It’s been a busy week for everyone concerned with a proposed, $1.6 billion merger between Charles River Laboratories International Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX). Aiming to counter stiff opposition from some of its top institutional investors, Charles River Labs issued a revised presentation this week highlighting the benefits of the deal […]
Webinar: Tips To Have Your Practice Succeed This Year
This on-demand webinar will offer insights and share tips on helping practices run more efficiently.
Charles River Labs seeks support for merger with WuXi
Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal with a new investor presentation and positive responses from clients. Looking to bolster support for its proposed, $1.6 billion merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), Charles River Laboratories International Inc. (NYSE:CRL) is mounting […]
WuXi PharmaTech merger under review in Caymans
The Grand Court of the Cayman Islands plans to review a controversial, $1.6 billion merger between WuXi PharmaTech (Cayman) Inc. (NYSE:WX) and Charles River Laboratories International Inc. (NYSE:CRL). Under the law of the Cayman Islands, where WuXi is incorporated, Grand Court approval is required to consummate the deal. WuXi said the court, equivalent to the […]
More balk at WuXi PharmaTech-Charles River deal
Two more top investors in Charles River Laboratories International Inc. (NYSE:CRL) voiced opposition to a proposed merger with WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal is too risky. Neuberger Berman LLC, in a June 16 letter to CRL’s board of directors, said the merger is not in the best interest of CRL’s shareholders and […]
Charles River Laboratories rebuffs investors protesting WuXi PharmaTech deal
Charles River Laboratories International Inc. (NYSE:CRL) responded to its largest shareholder’s protest about a proposed merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal was too good to pass up. In a letter to Jana Partners Inc. managing partner Barry Rosenstein, CRL CEO James Foster wrote that the hedge fund’s view of the […]